Abstract
Get full access to this article
View all access options for this article.
References
1.
Gillmore
JD
,
Gane
E
,
Taubel
J
, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 2021 DOI: 10.1056/NEJMoa2107454. https://www.nejm.org/doi/full/10.1056/NEJMoa2107454 (last accessed
July 10 , 2021
).
2.
Intellia Therapeutics and Regeneron Pharmaceuticals Intellia and Regeneron announce landmark clinical data showing deep reduction in disease-causing protein after single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis. 2021. https://ir.intelliatx.com/news-releases/news-release-details/intellia-and-regeneron-announce-landmark-clinical-data-showing (last accessed
July 10 , 2021
).
3.Prime Medicine. Prime Medicine launches with $315 million financing to deliver on the promise of prime editing. 2021 . https://www.primemedicine.com/media/prime-medicine-launches-to-deliver-on-the-promise-of-gene-editing (last accessed
July 15 , 2021
).
4.
Anzalone
AV
,
Randolph
PB
,
Davis
JR
, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 2019 DOI: 10.1038/s41586-019-1711-4. https://www.nature.com/articles/s41586-019-1711-4 (last accessed
July 15 , 2021
).
5.
Davies
K
. Precision chemistry on the genome:
interview with David
R
. Liu. Human Gene Therapy 2021;32:237–242, DOI: 10.1089/hum.2021.29151.int . https://www.liebertpub.com/doi/10.1089/hum.2021.29151.int (last accessed
July 15 , 2021
).
6.FUJIFILM Corporation. $850 million USD (¥90 billion yen) investment in FUJIFILM Diosynth Biotechnologies to add additional development and manufacturing capacity. 2021 . https://fujifilmdiosynth.com/about-us/press-releases/850-million-usd-%C2%A590-billion-yen-investment-in-fujifilm-diosynth-biotechnologies-to-add-additional-development-and-manufacturing-capacity/ (last accessed
July 10 , 2021
).
7.Biogen. Biogen announces topline results from phase 3 gene therapy study in choroideremia. 2021 . https://investors.biogen.com/news-releases/news-release-details/biogen-announces-topline-results-phase-3-gene-therapy-study (last accessed
July 13 , 2021
).
8.
4D Molecular Therapeutics. 4D Molecular Therapeutics announces rare disease ophthalmology product candidate portfolio update, including initial clinical safety and tolerability data for 4D-110 for choroideremia and 4D-125 for XLRP, and termination of Roche collaboration and license. https://4dmt.gcs-web.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-rare-disease-ophthalmology (last accessed
July 13 , 2021
).
9.
Kriya Therapeutics
. Kriya Therapeutics completes $100 million series B financing to advance its fully integrated platform for designing, developing and manufacturing transformative gene therapies. 2021. https://kriyatherapeutics.com/kriya-therapeutics-series-b-financing/ (last accessed
July 15 , 2021
).
10.
U.S. Securities and Exchange Commission
. Form S-1 registration statement of Tenaya Therapeutics, Inc. 2021. https://www.sec.gov/Archives/edgar/data/1858848/000119312521212010/d175698ds1.htm#toc175698_548/000119312521212010/d175698ds1.htm#toc175698_5 (last accessed
July 13 , 2021
).